Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of first-line osimertinib plus locally ablative radiotherapy for synchronous oligometastatic EGFR-mutant non-small cell lung cancer
KCT0007170Phase 2Completed
- Sponsor
- Yonsei University Health System
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by Yonsei University Health System. Started Jan 2023; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on KCT0007170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007170.